Impact Biomedical and Zoar Limited have cleared a regulatory milestone in their proposed business combination: Zoar’s registration statement for the deal became effective on October 23. Impact has scheduled a stockholder vote for November 13, moving the transaction toward a decision by Impact shareholders.
If the deal closes, the combined company is expected to operate as Zoar Limited and trade on NYSE American under the ticker ZOAR, subject to exchange approval.
Key details
- Stockholder vote: Impact’s special meeting is scheduled for November 13, 2026, at 10:00 a.m. Eastern. Shareholders will vote on the proposed business combination; the record date for determining who can vote is to be set by Impact’s board.
- Registration statement effective: The effectiveness of Zoar’s registration statement allows the companies to move ahead with the shareholder-vote process. It does not itself approve or complete the transaction.
- Expected name and ticker: Following closing, the combined company is expected to be called Zoar Limited and use the ticker symbol ZOAR on NYSE American, subject to listing approval.
- Companies involved: The proposed combination involves Impact Biomedical, Zoar Limited (formerly Dr. Ashley’s Limited) and Zoar Labs Limited (formerly Dr. Ashley’s Bio Labs Limited).
What changes now
The announcement marks progress toward a shareholder vote, but the business combination remains proposed. The filing does not provide new deal economics or say that the transaction has closed. If shareholders approve it and the other required steps are completed, the expected company name and ticker would change from Impact Biomedical and IBO to Zoar Limited and ZOAR.